Examination of the frequencies of specific myeloid populations in tumor tissue (Figure S2) surprisingly revealed significantly lower levels of macrophages (CD45+CD11b+F4/80+, Figure 2D) and DCs (CD45+CD11c+, Figure 2E) in tumors from the mice that were concomitantly treated with TTFields and anti-PD-1/anti-CTLA-4. The gene discussed is PTPRC; the disease is neoplasm.